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wi~ich provided protection against the effects of ischemia and raperfusion in a dose- 
dependent fashion. In addition, L-arginine eardioprotection was mediated by the activa- 
tion of guanyiate cyclaee leading to increased cGMP levels in human heart cells. The 
final effector of NO/cGMP may be the opening of KAT P channels. 
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411-5 L-Arginine for  Partial Reeynchronization of Abnormal  
Peripheral Vascular Reactivity in Heart Failure: A 
Prospective Randomized Double-Blind Study 
Moi~ammed Yousufuddirl, Mohamed Amrani, Waqar Shamim, Faisal AI-Nasser, Fouad 
Amin, Nicholas R. Banner, Andrew J S. Coats, Nationa/Heart and Lung/nstitute, 
London, United Kingdom. 
We investigated the effects of oral I-arginine (ARG) supplement on brachial artery (BA) 
reactivity in patient with CHF. Methods: Fiffy-men (59±10 yr.) with stable CHF of NYHA 
grade I-III and ejection fraction <40% were randomized to oral ARG or matching placebo 
for 1-week. Twenty-healthy men (57±9yr) with no clinical evidence of disease served as 
parallel controls for baseline comparison. BA reactivity was measured as a) flow-medi- 
ated dilation (FMD) in response to hyperemia induced by 5-min of distal forearm occlu- 
sion by blood pressure cuff, b) exercise-induced constriction (EIC) immediately after 
treadmill exemise, and c) resting, hyperemic and post-exeroise BA blood flow by high- 
resolution ultrasound technique using 8-11 MHz vascular probe connected to SONO 
5500 (Agilant Tech, USA). FMD and EIC were measured as % change in diameter of the 
BA after increased flow and exemise respectively. Exercise was performed with modified 
Bruce protocol and peak oxygen consumption (VO2) was measured (AMIS 2000, Den- 
mark). Exhaled nitric oxide (NO) was measured by a chemiluminescence analyzer. 
Investigations were performed after overnight fast under identical condition. Inferential 
statistics were restricted to CHF patients. Results: ARG and placebo patient-groups and 
controls were similar in demographics. Baseline characteristics were comparable 
between ARG and placebo groups in patients. Controls and patients differ in their BA 
reactivity and exercise capacity with former showing higher FMD and VO 2 but lower EIC 
(all P<0.0001). At one-wk FMD (2.24t-0.89 to2.6±1.1 Vs 2.3t0.32 to 2.3+1.07%;P=0.02) 
has increased while EIC (7.2±4.0 to 5.3±2.8 vs 5.9±3.2 to 5.8+3.1%;p=0.02) decreased 
with ARG supplementation compared to placebo in patients. Exhaled NO was increased, 
independent of changes in FMD or EIC in ARG arm compared to placebo (7.6±2.8 to 
9.4+3.4; vs 8.9-~2.5 to 9.4±3.4 parts per billion; P=0.01). Patients, who received ARG 
demonstrated a strong trend toward increase in exercise interval, VO2, and hyperamic 
blood flow compared to placebo group. Conclusion: ARG, via an increase in NO bioavial- 
ability, partially resynchronizes brachial artery reactivity towards normal in patients with 
CHF. 
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An Institutional Discharge Medication Program 
Reduces Future Cardiovascular Readmiselons and 
Mortality: An Analysis of 43,841 Patients With Coronary 
Artery Disease 
Robert R. Pearson. Benjamin D. Home, Chloe A. Allen Maycock, Donald L. Lappe', 
Susan Krelick-Goldberg, Tami L. Bair, Janette A. Orton, Diane S. Wallace, Haeli 
Hanseen, Dale G. Renlund, Joseph B. Muhlestein, LDS Hospital Salt Lake Ci~ Utah. 
Background: Patients (pts) admitted with a diagnosis of coronary artery disease (CAD) 
carry a significant risk of re-hospitalization or death during the year after discharge. We 
have shown that successful implementation of a multi-faceted ischarge medication pro- 
gram (DMP) increases the likelihood of CAD pts being discharged on appropriate medi. 
cal therapy (ASNAntiplatelet and a statin for all; Beta-Blockers post-MI). We 
hypothesized that this DMP would result in reduced cardiovascular eadmissions and 
mortality. 
Methods: We analyzed 43,841 pts discharged after a CAD-related hospitalization from 
10 hospitals within an integrated health care system. Implementation of the DMP was ini- 
tiated in 1/1999 and increased overall medication use from 65% to 95%. We compared 
one year cardiovascular eadmission or death rates of pts discharged between 1/1996- 
12/1998 (n=25,185) (pre-DMP) to pts discharged between 1/1999-6/2000 (n=18,656) 
(post-DMP). 
Results: Average pt age was 64±15 years; 62% were male; demographics did not differ 
between pre- and post-DMP groups. After controlling for age and gender in Cox regres- 
sion, post-DMP one-year re-admission rates were reduced from 20.4% to 17.7% (hazard 
ratio lHR]=0.86, p<0.001) and one-year mortality was reduced from 4.5% to 3.5% 
(HR--0.79, p<0.001). 
Conclusions: The successful implementation of an institutional cardiac DMP can signifi- 
cantly lower the rate at which pts with CAD are rsadmitted for cardiac complications and 
also will lower their mortality rates. 
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849-2 Quality of Care of Patients Admitted With Congeative 
Heart Failure: Influence of Physician Specialty end 
Hospital Type 
Jay K. Amin. Michael J. Lim, Yassar Almanaseer, Chih-Wen Pal, Gerdann Finnegen, Kim 
A. Eagle, Rajendre H. Mehta, University of Michigan, Ann Arbor, Michigan, Michigan 
Peer Review Organization, Plymouth, Michigan. 
Background: Congestive heart failure (CHF) is a common admission diagnosis in eld- 
edy patients (pts) in the United States. Increased resource utilization by CHF pts has 
generated great interest in improving quality of care for these pts. The impact of physi- 
cian specialty and hospital type on the quality of care has not been well studied. 
Methods: We evaluated 5871 Medicare beneficiadas admitted to 31 acute care hospitals 
in Southeast Michigan with CHF (1/98-12/98). Patients were identified retrospectively 
using ICD-9 codes for CHF. Indicators were evaluated with respect to physician specialty 
(cardiologist vs. non-cardiologist) and hospital type (teaching, n=17 vs. non-taaching, 
n=14). 
Results: Indicators are shown (Table). Patients treated by cardiologists had shorter 
length of stay (LOS, 5.5 vs. 6.0 days, p<.001) and similar 1-year mortality rates (37.9% 
vs. 35%, p=.06) compared to non-cardiologists. Patients treated in teaching hospitals 
had shorter LOS (5.6 vs. 6.1 days, p<.001) and lower 1-year mortality rates (34.7% vs. 
37.4%, p=.04). 
Conclusion: Quality of care for CHF pts tends to be less optimal in those treated by non- 
cardiologists and at non-teaching hospitals despite similar or higher mortality rates. This 
data supports the need for further educating non-cardiologists in the management of eld- 
erly pts admitted with CHF. In addition, it suggests that systemization of processes at 
non-teaching hospitals may improve the quality of care for CHF pts, thus leading to petter 
long-term outcomes. 
Quality Indicators Teaching Non- PValue Cardiologist, Non- PValue 
Hospital, teaching n=1297 cardiologist, 
n=3350 Hospital, n=3599 
n=2521 
Discharge ACE-inhibitor/ARB 81.6 73 <0.001 79.6 76.5 0.24 
(%) 
LVEF documented (%) 70.5 64.6 <0.001 65.3 68.3 0.05 
Discharge smoking cessation 24.0 34.5 0.08 28.1 27.9 0.98 
counseling (%) 
Discharge written instructions 97.0 97.3 0.75 97.8 97 0.43 
(%) 
Weights measured, >50% 68.4 61.6 0.006 77.7 62.6 <0.001 
hospital days (%) 
Discharge warfarin in CHF pts 48.7 41.7 0.16 56.5 39.1 <0.001 
with atrial fibrillation (%) 
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849-3 Regional Differences in Quality of Care for Heart 
Failure: The Role of Patient, Physician, and Hospltsl 
Characteristics 
Edward P. Havranek, Pare Wolfe, Frededck A. Masoudi, Hadan M. Krumholz, Saif S. 
Rathore, Beth Stevens, Diana L. Ordin, Colorado Foundation for Medical Care, Aurora, 
Colorado. 
Background: Quality of care for eldedy heart failure patients varies across the United 
States, but the extent to which patient, provider and hospital charecteristics contribute to 
this vadation is unknown. Methods: We used data from the National Heart Failure 
project, a Center for Medicare and Medicaid Services quality initiative that studied 37,500 
Medicare patients hospitalized with heart failure, to evaluate the extent to which patient, 
physician and hospital characteristics explain regional vadation in heart failure treatment. 
Small area variation for two quality indicators (QI)- documentation of ejection fraction 
(EF) and appropriate prescription of angiotansin converting enzyme inhibitor (ACEI)- was 
assessed by estimating the Ol rates by Hospitat Referral Regions (HRRs) in the United 
States using a non-linear mixed-effects model To identify variables associated with per- 
formance on the quality indicators by census divisions we used the method of general- 
ized estimating equations for a logistic model entenng HRR as a random effect. We 
compared the distribution of the predictors across regions using a chi-squara test for 
